SCHEMBL2270476

SCHEMBL2270476

CC(=O)CC(=O)OCC1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 2/20 0.46
GAA P10253 2/20 0.46
SI P14410 2/20 0.46
MGAM2 Q2M2H8 2/20 0.46
LMNA P02545 2/20 0.44
PTGIR P43119 4/20 0.34
SLC1A3 P43003 2/20 0.32
SLC1A2 P43004 2/20 0.32
SLC1A1 P43005 2/20 0.32
TDP1 Q9NUW8 1/20 0.31
CARM1 Q86X55 1/20 0.31
PRMT6 Q96LA8 1/20 0.31
PTGDR Q13258 2/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
JAK3 P52333 1/20 0.31
POLB P06746 1/20 0.31
PARP15 Q460N3 1/20 0.31
PARP10 Q53GL7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9774476 1.00 MGAM (0.46) MGAMGAASIMGAM2LMNA
SCHEMBL5139018 1.00 MGAM (0.46) MGAMGAASIMGAM2LMNA
SCHEMBL20954311 0.92 LMNA (0.55) MGAMGAASIMGAM2LMNA
SCHEMBL1322681 0.92 LMNA (0.50) MGAMGAASIMGAM2LMNA
SCHEMBL23048198 0.91 LMNA (0.50) MGAMGAASIMGAM2LMNA
SCHEMBL13425332 0.90 LMNA (0.58) MGAMGAASIMGAM2LMNA
SCHEMBL9933380 0.88 ALDH1A1 (0.49) MGAMGAASIMGAM2LMNA
SCHEMBL20954558 0.87 MGAM (0.39) MGAMGAASIMGAM2LMNA
SCHEMBL20185683 0.84 LMNA (0.43) MGAMGAASIMGAM2LMNA
SCHEMBL20954635 0.82 LMNA (0.39) MGAMGAASIMGAM2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111491935-B Novel analogs as modulators of androgen and glucocorticoid receptors 昂科斯特拉公司 2023-08-22 CN disclosed
EP-3707143-B9 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE S L (ES) 2023-04-12 EP disclosed
EP-3707143-B1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE S L (ES) 2022-12-28 EP disclosed
US-11453660-B2 Androgen receptor and glucocorticoid receptor modulators ONCOSTELLAE, S.L. 2022-09-27 US disclosed
US-20200325123-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE, S.L. (ES) 2020-10-15 US disclosed
EP-3707143-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS Oncostellae, S.L. (ES) 2020-09-16 EP disclosed
EP-3480201-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS Oncostellae, S.L. (ES) 2019-05-08 EP disclosed
CN-106632317-A 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and application thereof 江苏欧威医药有限公司 2017-05-10 CN disclosed
CN-104203945-B 1, 4-dihydro-naphthyridine derivatives, pharmaceutical compositions and uses thereof 江苏欧威医药有限公司 2017-01-18 CN disclosed
US-9284330-B2 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2016-03-15 US disclosed
EP-1910329-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE Bayer HealthCare AG (DE) 2008-04-16 EP disclosed
WO-2007025604-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE BAYER HEALTHCARE AG (DE) 2007-03-08 WO disclosed
WO-2007025604-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE BAYER HEALTHCARE AG (DE) 2007-03-08 WO disclosed
US-20060160801-A1 Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-20 US disclosed
EP-0162208-B1 NOVEL N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) 1989-11-23 EP disclosed
US-4683234-A HYPOTENSIVE AGENTS, ANTI-ANGINA SUNTORY LIMITED (JP) 1987-07-28 US disclosed
EP-0217142-A2 A polyazaheterocyclic compound Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1987-04-08 EP disclosed
EP-0162208-A2 Novel N-substituted 3,4-dihydropyrimidine derivatives, processes for preparing them and pharmaceutical compositions SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) 1985-11-27 EP disclosed
US-4446325-A VASODILATION, HYPOTENSIVE AGENTS MARUKO SEIYAKU CO., LTD. (JP) 1984-05-01 US disclosed
US-4179500-A 1,4-Dihydropyridine-sugar derivatives, and their use as medicaments BAYER AKTIENGESELLSCHAFT (DE) 1979-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160801-A1 Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes PTGIS, PTGIR, FPR1 MGAM 4680/4885GAA 3327/4885SI 4226/4885
US-20200325123-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS NR5A1, AR, NR3C1 MGAM 2651/4885GAA 3786/4885SI 3468/4885
US-11453660-B2 Androgen receptor and glucocorticoid receptor modulators AR, NR5A1, NR3C1 MGAM 2530/4885GAA 3692/4885SI 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.